FDA lifts clinical ban on Morrisville pharma's lead candidate
Morrisville drug developer Oxygen Biotherapeutics received good news from federal regulators when it heard that the FDA lifted a clinical ban on Oxygen’s leading product candidate.
The U.S. Food and Drug Administration had put a clinical hold on Oxycyte, the leading product developed by Oxygen Biotherapeutics (Nasdaq: OBXT) that would carry oxygen throughout the body, potentially reducing negative effects from a stroke or traumatic brain injury.
The clinical hold essentially stopped further development…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Jason deBruyn Source Type: research
More News: Brain | Food and Drug Administration (FDA) | Health Management | Neurology | Pharmaceuticals | Stroke